Soluble Membrane Attack Complex: Biochemistry and Immunobiology

被引:42
作者
Barnum, Scott R. [1 ]
Bubeck, Doryen [2 ]
Schein, Theresa N. [1 ]
机构
[1] CNine Biosolut LLC, Birmingham, AL 35205 USA
[2] Imperial Coll London, Dept Life Sci, London, England
基金
欧洲研究理事会; 美国国家卫生研究院;
关键词
complement; soluble membrane attack complex; sC5b-9; cholesterol-dependent cytolysins; MAC; diagnostics; sMAC; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ACTIVATED TERMINAL COMPLEMENT; CEREBROSPINAL-FLUID; SC5B-9; COMPLEX; S-PROTEIN; IN-VIVO; THROMBOTIC MICROANGIOPATHY; MONOCLONAL-ANTIBODIES; ALTERNATIVE PATHWAY; MULTIPLE-SCLEROSIS;
D O I
10.3389/fimmu.2020.585108
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The soluble membrane attack complex (sMAC, a.k.a., sC5b-9 or TCC) is generated on activation of complement and contains the complement proteins C5b, C6, C7, C8, C9 together with the regulatory proteins clusterin and/or vitronectin. sMAC is a member of the MACPF/cholesterol-dependent-cytolysin superfamily of pore-forming molecules that insert into lipid bilayers and disrupt cellular integrity and function. sMAC is a unique complement activation macromolecule as it is comprised of several different subunits. To date no complement-mediated function has been identified for sMAC. sMAC is present in blood and other body fluids under homeostatic conditions and there is abundant evidence documenting changes in sMAC levels during infection, autoimmune disease and trauma. Despite decades of scientific interest in sMAC, the mechanisms regulating its formation in healthy individuals and its biological functions in both health and disease remain poorly understood. Here, we review the structural differences between sMAC and its membrane counterpart, MAC, and examine sMAC immunobiology with respect to its presence in body fluids in health and disease. Finally, we discuss the diagnostic potential of sMAC for diagnostic and prognostic applications and potential utility as a companion diagnostic.
引用
收藏
页数:14
相关论文
共 227 条
[11]   The role of complement factor C3 in lipid metabolism [J].
Barbu, Andreea ;
Hamad, Osama A. ;
Lind, Lars ;
Ekdahl, Kristina N. ;
Nilsson, Bo .
MOLECULAR IMMUNOLOGY, 2015, 67 (01) :101-107
[12]   Complement: A primer for the coming therapeutic revolution [J].
Barnum, Scott R. .
PHARMACOLOGY & THERAPEUTICS, 2017, 172 :63-72
[13]   C4a: An Anaphylatoxin in Name Only [J].
Barnum, Scott R. .
JOURNAL OF INNATE IMMUNITY, 2015, 7 (04) :333-339
[14]  
Barnum SR, 2018, COMPLEMENT FACTSBOOK, V2nd, P480, DOI DOI 10.1016/C2015-0-06595-9
[15]   SOLUBLE TERMINAL COMPLEMENT COMPONENTS IN HUMAN MYASTHENIA-GRAVIS [J].
BAROHN, RJ ;
BREY, RL .
CLINICAL NEUROLOGY AND NEUROSURGERY, 1993, 95 (04) :285-290
[16]  
BAUER KA, 1989, BLOOD, V74, P2007
[17]  
BAUER KA, 1987, BLOOD, V70, P343
[18]  
BAUER KA, 1990, BLOOD, V76, P731
[19]   ACCUMULATION OF ANAPHYLATOXINS AND TERMINAL COMPLEMENT COMPLEXES IN INFLAMMATORY FLUIDS [J].
BENGTSSON, A ;
BENGTSON, JP ;
RYDENHAG, A ;
ROXVALL, L ;
HEIDEMAN, M .
JOURNAL OF INTERNAL MEDICINE, 1990, 228 (02) :173-176
[20]   An international serum standard for application in assays to detect human complement activation products [J].
Bergseth, Grethe ;
Ludviksen, Judith K. ;
Kirschfink, Michael ;
Giclas, Patricia C. ;
Nilsson, Bo ;
Mollnes, Tom E. .
MOLECULAR IMMUNOLOGY, 2013, 56 (03) :232-239